Inotrem receives approval to expand nangibotide clinical trial in critically ill COVID-19 patients and receive additional public funding of €45 million

Paris, July 12th. 2021. Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.

Read full article (PDF)